DNA Ligases Market Revenue to Attain USD 806.15 Mn by 2035
Published: 07 Jan 2026
Author: Precedence Research
DNA Ligases Market Revenue and Trends 2026 to 2035
The global DNA ligases market revenue surpassed USD 382.16 million in 2025 and is predicted to attain around USD 806.15 million by 2035, growing at a CAGR of 7.75%. This market is experiencing unprecedented growth, driven by the growing demand from molecular diagnostics, genetic engineering, and personalized medicine.
What are the Factors That Have a Significant Contribution to the Growth of the DNA ligases market?
The rising focus on personalized medicine and the expanding research for cell and gene therapies are the major drivers, contributing to the overall growth of the DNA ligases market during the forecast period. DNA ligases play a crucial role in developing tailored diagnostics and therapies for rare and genetic disorders. Several governments around the world and private players are heavily investing in life sciences, which boosts demand and supports relevant research. The market’s growth is also primarily supported by the rising advancement in gene editing & molecular biology technologies, particularly CRISPR-Cas9, which relies on DNA ligases for precise DNA assembly. Such factors are anticipated to fuel the market expansion in the coming years.
In addition, increasing use of next generation sequencing workflows and synthetic biology applications is expanding routine demand for high-fidelity DNA ligation enzymes. DNA ligases are also essential in cloning, library preparation, and DNA repair studies, strengthening their role across academic, clinical, and commercial laboratories. Continued funding for genomics infrastructure and translational research is further reinforcing sustained demand for advanced DNA ligase products.
Segment Insights
- By type, the T4 DNA ligase segment held the largest market share of 62.4% in 2025. The growth of the segment is primarily supported by its high efficiency and versatility for essential molecular biology tasks. In addition, the rising investment in personalized medicine, diagnostics, and gene-based therapies boosts the demand for T4 DNA ligases.
- By application, the genomics & genetic engineering segment led the DNA ligases market while holding the largest share of 67.8% in 2025, driven by critical applications in gene editing (CRISPR), recombinant DNA, molecular diagnostics (NGS), and synthetic biology.
- By end-user, the pharmaceutical & biotechnology companies segment held a market share of 42.4% in 2025. Pharmaceutical and biotechnology companies are increasingly focusing on developing gene therapies, drug discovery, personalized medicine, synthetic biology, and advanced diagnostics. These companies are the largest end-users and heavily influence the market’s growth through increasing R&D investments in advanced applications.
Regional Insights
The North America region dominates the global DNA ligases market by holding a share of 45.5% in 2025. The region holds a strong biotechnology and pharmaceutical ecosystem, significant R&D investment, a rising focus on cell & gene therapies, and increasing adoption of advanced molecular technologies such as CRISPR-based gene editing and next-generation sequencing. The region has a strong presence of major market players, such as Thermo Fisher Scientific, New England Biolabs, and Agilent Technologies, which are playing a crucial role in driving innovation and the market’s growth. These companies are investing heavily in genetic research, gene editing, and personalized medicine. The region has a robust network of academic research institutions, national laboratories, and clinical research centers that conduct extensive work in molecular biology, genomics, and genetic engineering, particularly in the United States and Canada.
Strong federal funding for genomics and translational research is accelerating large-scale sequencing and gene therapy programs that rely on high-performance DNA ligases. Increasing commercialization of cell and gene therapies is also expanding demand for clinical-grade enzymes that meet stringent quality and regulatory standards. Together, these factors are reinforcing North America’s leadership in both research-driven and clinical applications of DNA ligases.
On the other hand, the Asia Pacific region is a rapidly growing region and is projected to grow at a significant CAGR of approximately 8.5% from 2026 to 2035. The region's market growth is attributed to the rising investments in the biotech industry, increasing adoption of gene editing tools, such as CRISPR-Cas9, and strong government support. The increasing funding for R&D activities, particularly in countries such as China, Japan, and India, is spurring the demand for DNA ligases for research, synthetic biology, and advanced diagnostics. Additionally, the expanding applications in genomics, such as high-throughput sequencing (NGS) and molecular diagnostics (PCR), along with the rapid growth of personalized medicine, are anticipated to contribute to the regional market’s growth.
Growing establishment of genomics research institutes, biopharmaceutical manufacturing parks, and government-backed innovation clusters is strengthening regional enzyme demand. Local production of molecular biology reagents and increased collaboration between academic laboratories and biotech firms are improving supply accessibility and cost efficiency. These structural developments are reinforcing sustained adoption of DNA ligases across research and clinical laboratory settings in Asia Pacific.
DNA Ligases Market Coverage
| Report Attribute | Key Statistics |
| Market Revenue in 2025 | USD 382.16 Million |
| Market Revenue by 2035 | USD 806.15 Million |
| CAGR from 2026 to 2035 | 7.75% |
| Quantitative Units | Revenue in USD million/billion, Volume in units |
| Largest Market | North America |
| Base Year | 2025 |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa |
Recent Developments
- In October 2024, Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of the FlexPrep Ultra-High Throughput Library Preparation Kit, designed with a proprietary Twist-developed enzyme to enable throughput at a low cost, and accelerate the adoption of NGS by microarray users in population and agricultural genomics (agrigenomics).(Source: https://www.businesswire.com)
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7282
You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344